Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for IDRSF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -161.54M
March 31, 2026 -171.00M
December 31, 2025 -211.27M
September 30, 2025 -164.21M
June 30, 2025 -250.27M
March 31, 2025 -305.28M
December 31, 2024 -366.33M
September 30, 2024 -484.07M
June 30, 2024 -454.15M
March 31, 2024 -560.32M
December 31, 2023 -695.27M
September 30, 2023 -799.39M
June 30, 2023 -915.66M
March 31, 2023 -913.77M
December 31, 2022 -901.05M
September 30, 2022 -886.41M
June 30, 2022 -810.52M
March 31, 2022 -736.77M
Date Value
December 31, 2021 -644.95M
September 30, 2021 -566.87M
June 30, 2021 -539.79M
March 31, 2021 -447.19M
December 31, 2020 -390.89M
September 30, 2020 -381.85M
June 30, 2020 -408.49M
March 31, 2020 -465.03M
December 31, 2019 -465.16M
September 30, 2019 -462.89M
June 30, 2019 -431.60M
March 31, 2019 -394.58M
December 31, 2018 -359.65M
September 30, 2018 -86.81M
June 30, 2018 -48.65M
March 31, 2018 119.06M
December 31, 2017 97.26M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Basilea Pharmaceutica AG 75.01M
Santhera Pharmaceuticals Holding AG -43.47M
BeOne Medicines Ltd. 1.488B
AC Immune SA --
CRISPR Therapeutics AG -369.58M